Insider filing report for Changes in Beneficial Ownership
- Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
- Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13G
|
UNDER THE SECURITIES EXCHANGE ACT OF 1934
|
(Amendment No. 1)*
|
Ceribell, Inc. (Name of Issuer) |
Common Stock, $0.001 par value per share (Title of Class of Securities) |
15678C102 (CUSIP Number) |
12/09/2024 (Date of Event Which Requires Filing of this Statement) |
| Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
 Rule 13d-1(b)
|
 Rule 13d-1(c)
|
| Rule 13d-1(d)
|
SCHEDULE 13G
|
| CUSIP No. | 15678C102 |
| 1 | Names of Reporting Persons
ABG WTT-Ceribell Limited | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
CAYMAN ISLANDS
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
1,691,267.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
4.6 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
OO |
Comment for Type of Reporting Person: The percentage of ownership based on 37,095,690 shares of Common Stock of the Issuer outstanding as of October 31, 2025, as reported on the Issuer's Form 10-Q filed on November 4, 2025.
SCHEDULE 13G
|
| CUSIP No. | 15678C102 |
| 1 | Names of Reporting Persons
ABG V-Ceribell Limited | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
CAYMAN ISLANDS
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
1,691,267.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
4.6 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
CO |
Comment for Type of Reporting Person: ABG V-Ceribell Limited is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited. The percentage of ownership based on 37,095,690 shares of Common Stock of the Issuer outstanding as of October 31, 2025, as reported on the Issuer's Form 10-Q filed on November 4, 2025.
SCHEDULE 13G
|
| CUSIP No. | 15678C102 |
| 1 | Names of Reporting Persons
Ally Bridge Group Global Life Science Capital Partners V, L.P. | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
CAYMAN ISLANDS
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
1,691,267.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
4.6 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person: Ally Bridge Group Global Life Science Capital Partners V, L.P. is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited. The percentage of ownership based on 37,095,690 shares of Common Stock of the Issuer outstanding as of October 31, 2025, as reported on the Issuer's Form 10-Q filed on November 4, 2025.
SCHEDULE 13G
|
| CUSIP No. | 15678C102 |
| 1 | Names of Reporting Persons
ABG Global Life Science Capital Partners V GP, L.P. | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
CAYMAN ISLANDS
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
1,691,267.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
4.6 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person: ABG Global Life Science Capital Partners V GP, L.P. is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited. The percentage of ownership based on 37,095,690 shares of Common Stock of the Issuer outstanding as of October 31, 2025, as reported on the Issuer's Form 10-Q filed on November 4, 2025.
SCHEDULE 13G
|
| CUSIP No. | 15678C102 |
| 1 | Names of Reporting Persons
ABG Global Life Science Capital Partners V GP Limited | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
CAYMAN ISLANDS
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
1,691,267.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
4.6 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
CO |
Comment for Type of Reporting Person: ABG Global Life Science Capital Partners V GP Limited is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited. The percentage of ownership based on 37,095,690 shares of Common Stock of the Issuer outstanding as of October 31, 2025, as reported on the Issuer's Form 10-Q filed on November 4, 2025.
SCHEDULE 13G
|
| CUSIP No. | 15678C102 |
| 1 | Names of Reporting Persons
Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
CAYMAN ISLANDS
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
1,691,267.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
4.6 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person: Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited. The percentage of ownership based on 37,095,690 shares of Common Stock of the Issuer outstanding as of October 31, 2025, as reported on the Issuer's Form 10-Q filed on November 4, 2025.
SCHEDULE 13G
|
| CUSIP No. | 15678C102 |
| 1 | Names of Reporting Persons
ABG-WTT Global Life Science Capital Partners GP, L.P. | ||||||||
| 2 |
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
CAYMAN ISLANDS
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
1,691,267.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
4.6 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person: ABG-WTT Global Life Science Capital Partners GP, L.P. is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited. The percentage of ownership based on 37,095,690 shares of Common Stock of the Issuer outstanding as of October 31, 2025, as reported on the Issuer's Form 10-Q filed on November 4, 2025.
SCHEDULE 13G
|
| CUSIP No. | 15678C102 |
| 1 | Names of Reporting Persons
ABG-WTT Global Life Science Capital Partners GP Limited | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
CAYMAN ISLANDS
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
1,691,267.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
4.6 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
CO |
Comment for Type of Reporting Person: ABG-WTT Global Life Science Capital Partners GP Limited is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited. The percentage of ownership based on 37,095,690 shares of Common Stock of the Issuer outstanding as of October 31, 2025, as reported on the Issuer's Form 10-Q filed on November 4, 2025.
SCHEDULE 13G
|
| CUSIP No. | 15678C102 |
| 1 | Names of Reporting Persons
ABG Management Ltd. | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
CAYMAN ISLANDS
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
1,691,267.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
4.6 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
CO |
Comment for Type of Reporting Person: ABG Management Ltd. is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited. The percentage of ownership based on 37,095,690 shares of Common Stock of the Issuer outstanding as of October 31, 2025, as reported on the Issuer's Form 10-Q filed on November 4, 2025
SCHEDULE 13G
|
| CUSIP No. | 15678C102 |
| 1 | Names of Reporting Persons
Ally Bridge Group (PE) LLC | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
1,691,267.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
4.6 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
IA, OO |
Comment for Type of Reporting Person: Ally Bridge Group (PE) LLC is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited. The percentage of ownership based on 37,095,690 shares of Common Stock of the Issuer outstanding as of October 31, 2025, as reported on the Issuer's Form 10-Q filed on November 4, 2025.
SCHEDULE 13G
|
| CUSIP No. | 15678C102 |
| 1 | Names of Reporting Persons
Fan Yu | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
MALTA
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
1,691,267.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
4.6 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
IN |
Comment for Type of Reporting Person: Fan Yu is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited. The percentage of ownership based on 37,095,690 shares of Common Stock of the Issuer outstanding as of October 31, 2025, as reported on the Issuer's Form 10-Q filed on November 4, 2025.
SCHEDULE 13G
|
| Item 1. | ||
| (a) | Name of issuer:
Ceribell, Inc. | |
| (b) | Address of issuer's principal executive offices:
360 N. Pastoria Avenue, Sunnyvale, California 94085 | |
| Item 2. | ||
| (a) | Name of person filing:
ABG WTT-Ceribell Limited ABG V-Ceribell Limited Ally Bridge Group Global Life Science Capital Partners V, L.P. ABG Global Life Science Capital Partners V GP, L.P. ABG Global Life Science Capital Partners V GP Limited Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. ABG-WTT Global Life Science Capital Partners GP, L.P. ABG-WTT Global Life Science Capital Partners GP Limited ABG Management Ltd. Ally Bridge Group (PE) LLC Fan Yu | |
| (b) | Address or principal business office or, if none, residence:
ABG WTT-Ceribell Limited c/o Maples Corporate Services Limited Ugland House, Grand Cayman Cayman Islands KY1-1104 ABG V-Ceribell Limited c/o Maples Corporate Services Limited Ugland House, Grand Cayman Cayman Islands KY1-1104 Ally Bridge Group Global Life Science Capital Partners V, L.P. c/o Maples Corporate Services Limited Ugland House, Grand Cayman Cayman Islands KY1-1104 ABG Global Life Science Capital Partners V GP, L.P. c/o Maples Corporate Services Limited Ugland House, Grand Cayman Cayman Islands KY1-1104 ABG Global Life Science Capital Partners V GP Limited c/o Maples Corporate Services Limited Ugland House, Grand Cayman Cayman Islands KY1-1104 Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. c/o Maples Corporate Services Limited Ugland House, Grand Cayman Cayman Islands KY1-1104 ABG-WTT Global Life Science Capital Partners GP, L.P. c/o Maples Corporate Services Limited Ugland House, Grand Cayman Cayman Islands KY1-1104 ABG-WTT Global Life Science Capital Partners GP Limited c/o Maples Corporate Services Limited Ugland House, Grand Cayman Cayman Islands KY1-1104 ABG Management Ltd. c/o Maples Corporate Services Limited Ugland House, Grand Cayman Cayman Islands KY1-1104 Ally Bridge Group (PE) LLC 430 Park Avenue New York, New York 10022 United States of America Fan Yu c/o Maples Corporate Services Limited Ugland House, Grand Cayman Cayman Islands KY1-1104 | |
| (c) | Citizenship:
ABG WTT-Ceribell Limited - Cayman Islands ABG V-Ceribell Limited - Cayman Islands Ally Bridge Group Global Life Science Capital Partners V, L.P. - Cayman Islands ABG Global Life Science Capital Partners V GP, L.P. - Cayman Islands ABG Global Life Science Capital Partners V GP Limited - Cayman Islands Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. - Cayman Islands ABG-WTT Global Life Science Capital Partners GP, L.P. - Cayman Islands ABG-WTT Global Life Science Capital Partners GP Limited - Cayman Islands ABG Management Ltd.- Cayman Islands Ally Bridge Group (PE) LLC - Delaware Fan Yu - Malta | |
| (d) | Title of class of securities:
Common Stock, $0.001 par value per share | |
| (e) | CUSIP No.:
15678C102 | |
| Item 3. | If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: | |
| (a) | Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
| |
| (b) | Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
| |
| (c) | Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
| |
| (d) | Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
| |
| (e) | An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
| |
| (f) | An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
| |
| (g) | A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
| |
| (h) | A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
| |
| (i) | A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
| |
| (j) | A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution: | |
| (k) | Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
| |
| Item 4. | Ownership | |
| (a) | Amount beneficially owned:
ABG WTT-Ceribell Limited: 1,691,267 ABG V-Ceribell Limited: 1,691,267 Ally Bridge Group Global Life Science Capital Partners V, L.P.: 1,691,267 ABG Global Life Science Capital Partners V GP, L.P.: 1,691,267 ABG Global Life Science Capital Partners V GP Limited: 1,691,267 Ally Bridge Group-WTT Global Life Science Capital Partners, L.P.: 1,691,267 ABG-WTT Global Life Science Capital Partners GP, L.P.: 1,691,267 ABG-WTT Global Life Science Capital Partners GP Limited: 1,691,267 ABG Management Ltd.: 1,691,267 Ally Bridge Group (PE) LLC: 1,691,267 Fan Yu: 1,691,267 | |
| (b) | Percent of class:
ABG WTT-Ceribell Limited: 4.6% ABG V-Ceribell Limited: 4.6% Ally Bridge Group Global Life Science Capital Partners V, L.P. : 4.6% ABG Global Life Science Capital Partners V GP, L.P. : 4.6% ABG Global Life Science Capital Partners V GP Limited: 4.6% Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. : 4.6% ABG-WTT Global Life Science Capital Partners GP, L.P.: 4.6% ABG-WTT Global Life Science Capital Partners GP Limited: 4.6% ABG Management Ltd.: 4.6% Ally Bridge Group (PE) LLC: 4.6% Fan Yu: 4.6% %
| |
| (c) | Number of shares as to which the person has:
| |
| (i) Sole power to vote or to direct the vote:
ABG WTT-Ceribell Limited: 0 ABG V-Ceribell Limited: 0 Ally Bridge Group Global Life Science Capital Partners V, L.P. : 0 ABG Global Life Science Capital Partners V GP, L.P. : 0 ABG Global Life Science Capital Partners V GP Limited: 0 Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. : 0 ABG-WTT Global Life Science Capital Partners GP, L.P.: 0 ABG-WTT Global Life Science Capital Partners GP Limited: 0 ABG Management Ltd.: 0 Ally Bridge Group (PE) LLC: 0 Fan Yu: 0 | ||
| (ii) Shared power to vote or to direct the vote:
ABG WTT-Ceribell Limited: 1,691,267 ABG V-Ceribell Limited: 1,691,267 Ally Bridge Group Global Life Science Capital Partners V, L.P.: 1,691,267 ABG Global Life Science Capital Partners V GP, L.P.: 1,691,267 ABG Global Life Science Capital Partners V GP Limited: 1,691,267 Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. : 1,691,267 ABG-WTT Global Life Science Capital Partners GP, L.P.: 1,691,267 ABG-WTT Global Life Science Capital Partners GP Limited: 1,691,267 ABG Management Ltd.: 1,691,267 Ally Bridge Group (PE) LLC: 1,691,267 Fan Yu: 1,691,267 | ||
| (iii) Sole power to dispose or to direct the disposition of:
ABG WTT-Ceribell Limited: 0 ABG V-Ceribell Limited: 0 Ally Bridge Group Global Life Science Capital Partners V, L.P. : 0 ABG Global Life Science Capital Partners V GP, L.P. : 0 ABG Global Life Science Capital Partners V GP Limited: 0 Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. : 0 ABG-WTT Global Life Science Capital Partners GP, L.P.: 0 ABG-WTT Global Life Science Capital Partners GP Limited: 0 ABG Management Ltd.: 0 Ally Bridge Group (PE) LLC: 0 Fan Yu: 0 | ||
| (iv) Shared power to dispose or to direct the disposition of:
ABG WTT-Ceribell Limited: 1,691,267 ABG V-Ceribell Limited: 1,691,267 Ally Bridge Group Global Life Science Capital Partners V, L.P.: 1,691,267 ABG Global Life Science Capital Partners V GP, L.P.: 1,691,267 ABG Global Life Science Capital Partners V GP Limited: 1,691,267 Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. : 1,691,267 ABG-WTT Global Life Science Capital Partners GP, L.P.: 1,691,267 ABG-WTT Global Life Science Capital Partners GP Limited: 1,691,267 ABG Management Ltd.: 1,691,267 Ally Bridge Group (PE) LLC: 1,691,267 Fan Yu: 1,691,267 | ||
| Item 5. | Ownership of 5 Percent or Less of a Class. | |
|
Ownership of 5 percent or less of a class
| ||
| Item 6. | Ownership of more than 5 Percent on Behalf of Another Person. | |
Not Applicable
| ||
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. | |
Not Applicable
| ||
| Item 8. | Identification and Classification of Members of the Group. | |
Not Applicable
| ||
| Item 9. | Notice of Dissolution of Group. | |
Not Applicable
| ||
| Item 10. | Certifications: |
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. |
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comments accompanying signature: The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature. Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent. Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).